SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Apricus Biosciences
An SI Board Since September 2014
Posts SubjectMarks Bans Symbol
2026 18 0 APRI
Emcee:  mokelumne river Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
251Food for Thought I recently have began searching for any information I can findMirror Image-11/6/2014
250James I agree that the strategy is also the fact that more than one drug can comeico20-11/6/2014
249Well, they better pull their fingers out their arses and get started soon or thiphoenix_rising-11/5/2014
248Eman, thanks as I was struggling with Starbuck's question. I again listenedmokelumne river-11/5/2014
247great post James, Fispemifene has 2 advantages, it also helps with urinary flow eico20-11/5/2014
246Androxal has a two year lead on Fispemifene, so if it is approved it would seem Starbuck2-11/5/2014
245Our Fispemifene wagon seems to be hitched to the FDA’s actions on Repros Therapemokelumne river111/5/2014
244A block of 43´000 shares no move, but 300 shares to drop it 4 cents....Hellsails-11/5/2014
243We now know the difference between "initiated" and "commence"mokelumne river-11/5/2014
242It does seem like a change of pace. Good - I hope that management now understandMirror Image-11/5/2014
2413 conferences in a month...wow!. The new IR company really is managing to influphoenix_rising-11/5/2014
240My bad (mea culpa) Strong Long. I cut off the usual description of Apricus in tmokelumne river-11/4/2014
239Things that stood out to me in yesterday's press release. Why Vytaros versuStrong Long-11/4/2014
238good to know, it takes time to get a new drug selling.eico20-11/4/2014
237Just as info. I have been a bit worried when i haven´t been able to find anHellsails-11/4/2014
236I agree p-r, minimal rev in Q3, the best chance of good news would be more repoeico20-11/4/2014
235good question MI, I will try to get an answer from D. Collins on that and reporteico20-11/4/2014
234I don't expect to see much in the way of sales this quarter since we will onphoenix_rising-11/4/2014
233I just got the answer... Apricus Biosciences Announces Corporate Update and ThHellsails-11/4/2014
232Shouldn´t we get soon a quartely report ? and , will we see some figures aHellsails-11/4/2014
231Question on Fispemifene When I read the original press release the day that AprMirror Image-11/4/2014
230Just to clarify, from the 10K on the Sandoz License: "In December 2013, wemokelumne river111/3/2014
229The launch of " Vytaros(R)" by Sandoz in Belgium is welcome news: finmokelumne river111/3/2014
228great Post James, I agree with your perspectives on the FDA meeting and prospecteico20-11/2/2014
227Skip those links. I'm not sure it's legit. It seems when I search for ViShazam619-11/2/2014
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News